Patent intelligence · US
US 11040965
Process for making Hepatitis B core protein modulators
Process for making Hepatitis B core protein modulators
Patent details — US 11040965
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 22, 2021
- Expiration
- Jun 17, 2041
- Applicant
- ASSEMBLY BIOSCIENCES, INC.
- Claims
- 17
- CPC classes
- A61P, A61P31/20
Quick answer
US 11040965 (Process for making Hepatitis B core protein modulators) is held by ASSEMBLY BIOSCIENCES, INC.. Status: granted. Granted Jun 22, 2021. Expires Jun 17, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASSEMBLY BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P31/20
More from ASSEMBLY BIOSCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12030869
5-membered heteroaryl carboxamide compounds for treatment of HBV
granted -
US 11814376
Hepatitis b core protein modulators
granted -
US 11560370
5-membered heteroaryl carboxamide compounds for treatment of HBV
granted -
US 11331365
Multispecific protein drug and library thereof, preparing method therefor and application thereof
granted -
US 11078170
Cyclic sulfamide compounds and methods of using same
granted -
US 10987360
Hepatitis B core protein modulators
granted -
US 10968211
Hepatitis B core protein modulators
granted
Frequently asked questions
What is US patent 11040965?
US 11040965 (Process for making Hepatitis B core protein modulators) is held by ASSEMBLY BIOSCIENCES, INC.. Status: granted. Granted Jun 22, 2021. Expires Jun 17, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11040965?
ASSEMBLY BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11040965 expire?
Our index shows an expiration date of Jun 17, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.